[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341101-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341101-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","proton-beam-therapy-for-clival-chordoma-optimising-rare-cancer-treatments-in-australia","Proton beam therapy for clival chordoma - Optimising rare cancer treatments in Australia","","Proton beam therapy is positioned as a key addition to Australia’s existing cancer treatment options with the anticipated launch of the Australian Bragg Centre for Proton Therapy and Research in Adelaide. The benefits are highlighted for rare clival chordomas, where tumour anatomy threatens critical structures and radio-resistance limits conventional radiation therapy effectiveness. The review synthesises major study findings and assesses evidence for management strategies, including effects of institutional volume and multidisciplinary team care on patient outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proton-beam-therapy-for-clival-chordoma-optimising-rare-cancer-treatments-in-australia/341101/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proton-beam-therapy-for-clival-chordoma-optimising-rare-cancer-treatments-in-australia/341101.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are clival chordomas considered difficult to treat?","Question",{"text":63,"@type":64},"Clival chordomas are challenging because of their anatomical proximity to critical structures and their inherent radio-resistance to conventional radiation therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What has historically been the standard treatment approach for clival chordoma?",{"text":68,"@type":64},"Standard care focuses on achieving maximal safe surgical removal or gross total resection, followed by adjuvant radiotherapy to a reported dose range of 55–80 Gy.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the review describe the evidence landscape for this rare cancer?",{"text":72,"@type":64},"Because of the low incidence of the malignancy, high-quality randomized trial evidence is limited, and much of the evidence relies on large case series from higher-volume centers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341101,1790195057,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","REVIEW ARTICLE  \nProton beam therapy for clival chordoma: Optimising rare cancer treatments in Australia  \nAshwathy Mathew, MBBS, MD, DNB 1 , Peter Gorayski, BSc (Hons), BMBS, FRACGP, FRANZCR 1,2,3 , Nicholas Candy, MBBS, MS4,5,6, Frank Saran, MD, FRCR, FRANZCR 1,2, & Hien Le, MBBS, FRANZCR 1,2,3 1Department of Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia  \n2Australian Bragg Centre for Proton Therapy and Research, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia  \n3Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia 4Department of Surgery, The University of Adelaide, Adelaide, South Australia, Australia 5Department of Neurosurgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia  \n6Department of Surgery-Otolaryngology, Head & Neck Surgery, University of Adelaide, Adelaide, South Australia, Australia  \nKeywords  \ncancer, Chordoma, proton therapy, radiation therapy, rare cancers, sarcoma  \nCorrespondence  \nPeter Gorayski, Australian Bragg Centre for Proton Therapy and Research, South Australian Health and Medical Research Institute, PO Box 11060, Adelaide 5001, South Australia, Australia. Tel: +61 (8) 8128 4000; E-mail: [peter.gorayski@unisa.edu.au](peter.gorayski@unisa.edu.au)  \n[Received: 7 September 2023](Received: 7 September 2023); [Accepted: 9](Accepted: 9)[ ](Accepted: 9)February 2024  \nJ Med Radiat Sci 71 (2024) 47–58  \nAbstract  \nWith the anticipated launch of the Australian Bragg Centre for Proton Therapy and Research (ABCPTR) in Adelaide, Australia, proton therapy will become asigniﬁcant addition to existing cancer treatment options for Australians. The anticipated beneﬁts will be particularly evident in rare cancers such as clival chordomas, a challenging tumour entity due to the anatomical relationship with critical structures, and proven radio-resistance to conventional radiation therapy. The article synthesises key ﬁndings from major studies and evaluates the current evidence supporting various management strategies for clival chordomas. It also considers the inﬂuence of institutional volume and multidisciplinary team management on patient outcomes and outlines how high-quality care can be effectively delivered within the Australian healthcare system, emphasising the potential impact of proton therapy on the treatment paradigm of clival chordomas in Australia.  \ndoi: 10.1002/jmrs.774  \nIntroduction  \nChordomas are rare, malignant, locally aggressive neoplasms that typically originate in the axial skeleton, embryologically arising from the remnants of the notochord. The estimated number of Australian adult patients with skull base chordomas in 2025 is expected tobe around 31 per year, making it a rare tumour within the Australian context. 1,2 Skull base chordomas account for 26–32% of all chordomas.3,4 Of these, 49% arise in the clivus, 32% in the sphenoclival region, 9% in the petroclival region, 6% in the cervical spine, and 4% in other areas. In children and young adults up to the age of 20, chordomas are more frequently located at the skull base (70%) compared to older patients (21%) . 1,3 Unless detected incidentally, patients frequently present at an  \nadvanced stage of their disease, characterised by sizable tumours. The primary surgical objective of achieving a complete excision becomes exceptionally challenging due to the frequent inﬁltration of the brainstem, cranial nerves, and major blood vessels by the tumour.3 Adding to the challenge of achieving optimal local control and overall survival rates is the inherent ‘radio-resistance’ of these tumours, as evidenced by a low a/b ratio of approximately 2.45,5 necessitating the administration of elevated radiation doses for effective tumour control. Consequently, the primary recurrence pattern observed in skull base chordomas is local relapse, either as the sole site of recurrence or as a component of","cbCaifWp5c2BfKYi","https://ap.wps.com/l/cbCaifWp5c2BfKYi","pdf",281902,12,"English","# Introduction\n## Clinical challenges and radio-resistance\n# Management strategies\n## Surgical approach and adjuvant radiotherapy\n## Evidence base and treatment evidence gaps\n# Treatment delivery considerations\n## Radiation dose requirements and toxicity risks\n# Patient outcomes in practice","[{\"question\":\"Why are clival chordomas considered difficult to treat?\",\"answer\":\"Clival chordomas are challenging because of their anatomical proximity to critical structures and their inherent radio-resistance to conventional radiation therapy.\"},{\"question\":\"What has historically been the standard treatment approach for clival chordoma?\",\"answer\":\"Standard care focuses on achieving maximal safe surgical removal or gross total resection, followed by adjuvant radiotherapy to a reported dose range of 55–80 Gy.\"},{\"question\":\"How does the review describe the evidence landscape for this rare cancer?\",\"answer\":\"Because of the low incidence of the malignancy, high-quality randomized trial evidence is limited, and much of the evidence relies on large case series from higher-volume centers.\"}]","Proton beam therapy for clival chordoma - Optimising rare cancer treatments in Australia | PDF",1790040330,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15b2e74922b5357fadd7a43c707d7d09.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f8edbe13eb1bca686604917b908110.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2d2922b5d2f14f66c3126e8c26d320d.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0113338ba6763546b72071688c32889.webp",980,1287]